Clinical Trials Logo

Lung Transplant Rejection clinical trials

View clinical trials related to Lung Transplant Rejection.

Filter by:

NCT ID: NCT06309628 Enrolling by invitation - Clinical trials for Lung Transplant Rejection

Analysis of Volatile Organic Compounds in the Breath of Lung Transplant Rejection Patients Using Infrared Spectroscopy

Start date: September 21, 2023
Phase:
Study type: Observational

This study will sample and analyze volatile organic compounds (VOCs) from participants considered to be at risk for developing rejection following lung transplant by using infrared spectroscopy.

NCT ID: NCT06302556 Not yet recruiting - Clinical trials for Lung Transplant Rejection

The Role of Immune Checkpoints in Lung Transplant (ILTRA)

ILTRA
Start date: April 2024
Phase:
Study type: Observational

The goal of this observational study is to learn about rejection in lung transplantation. The main question it aims to answer is: • what is the role of immune checkpoints in lung transplantation? Participants will describe pathways of rejection in lung transplantation analyzing the immune checkpoints on explanted lungs as well as trans-bronchial biopsies.

NCT ID: NCT06203964 Active, not recruiting - Clinical trials for Lung Transplant Rejection

Organizing Pneumonia in Lung Transplant Recipients, a Restrospective Exploratory Study (OPIL-Study)

OPIL
Start date: July 7, 2023
Phase:
Study type: Observational

The aim of this study is to generate evidence regarding organizing pneumonia in lung transplant recipients.

NCT ID: NCT06112951 Recruiting - Clinical trials for Lung Transplant Rejection

A Prospective Randomized Trial of ECP in Subclinical AMR

EXPORT-DSA
Start date: March 1, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to evaluate the therapeutic effect of extracorporeal photopheresis in subclinical antibody-mediated rejection after lung transplantation.The main questions it aims to answer are: 1. Does ECP therapy result in a significant reduction in MFI (Mean Fluorescence Intensity) from the baseline MFI in clinically stable patients with persistent (>6 months) dnDSAs (MFI>1000)? 2. What is the impact of ECP therapy on the following outcomes in these patients: ACR, clinical AMR, CLAD, infections, drop-out rate, survival, adverse events? Participants will be randomized into two groups. Each group will include 40 patients. The control group will be observed and no active treatment will be administered. The treatment group will receive extracorporeal photopheresis. First, a two-day treatment cycle will be performed once every second week for the first two months. Then, a two-day treatment cycle will be performed once a month for 6 months. Researchers will compare the two groups regarding: MFI value, development of ACR, clinical AMR, CLAD, infections, survival, adverse events, immunophenotyping, miRNA expression profiling, cytokine expression, gene expression signature of PBMCs and proteomic characterization.

NCT ID: NCT06082037 Recruiting - Clinical trials for Lung Transplant Rejection

A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction

ROCKaspire
Start date: October 10, 2023
Phase: Phase 3
Study type: Interventional

This double-blind, randomized, placebo-controlled, multinational, multicenter, parallel-group, Phase 3, 2-arm, study will investigate the efficacy and safety of belumosudil compared with placebo, both administered on top of azithromycin and standard-of-care regimen of immunosuppression in male or female participants at least 1 year after bilateral lung transplant, who are at least 18 years of age and who have evidence of progressive CLAD despite azithromycin therapy. Study details include: The study duration will be up to 31 weeks for participants not entering the open-label extension (OLE) period and up to 57 weeks for participants entering the OLE period but not the long-term OLE. The treatment duration will be up to 26 weeks for participants not entering the OLE period and up to 52 weeks for participants entering the OLE period but not the long-term OLE. The number of visits will be up to 10 visits for participants not entering the OLE period and up to 16 visits for participants entering the OLE period but not the long-term OLE. For participants who enter the long-term OLE, treatment and study participation will continue with visits every 12 weeks per protocol specifications.

NCT ID: NCT05792384 Not yet recruiting - Clinical trials for Lung Transplant Rejection

Study of Transbronchial Cryobiopsy in Monitoring Complications of Lung Transplantation

Start date: April 6, 2023
Phase: N/A
Study type: Interventional

The goal of this randomized controlled trial is to compare the diagnostic efficacy and safety of transbronchial cryobiopsy (TBCB) and traditional transbronchial lung biopsy for diagnosing the lung transplantation rejection , so as to establish the evidence-based medical basis for the effectiveness and safety of TBCB for monitoring after lung transplantation, It is expected to provide a better auxiliary examination method for lung transplantation. The main questions it aims to answer are: (1) Histopathological evaluability of specimens; (2) Safety of TBCB; (3) Size and quality of specimen, and number of attempts to obtain five samples. Participants will undergo TBCB with 1.1 mm flexible cryoprobe or traditional transbronchial lung biopsy with biopsy forceps.

NCT ID: NCT05721079 Completed - Clinical trials for Lung Transplant Rejection

Extracorporeal Photopheresis (ECP) After Lung Transplantation

Start date: March 1, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the use of ECP for lung-transplanted patients to reduce the occurrence of acute and chronic rejection and CMV-infection.

NCT ID: NCT05655208 Completed - Clinical trials for Lung Transplant Rejection

Histological Profiles of Lung Allograft Transbronchial Biopsies and Clinical Outcomes After Lung Transplantation

LANDSCAPE
Start date: February 1, 2010
Phase:
Study type: Observational

Lung transplantation is the only curative treatment for individuals with end-stage lung disease. Understanding the lung allograft's histological lesions, which is key for the patient management, remains difficult because of the multiplicity of lesions associated with graft outcome and their interpenetration. The goal of this observational study is to identify clusters of histological lesion on transbronchial biopsies in Lung transplant recipient prospective cohort. The main question[s] it aims to answer are: - what are the different pattern of histological lesion? - what are the graft outcome associated with the different clusters?

NCT ID: NCT05550662 Not yet recruiting - Clinical trials for Lung Transplant Rejection

HP 129Xe MRI for Evaluation of CLAD in Lung Transplant Recipients

Start date: December 1, 2023
Phase: Phase 2
Study type: Interventional

To evaluate the feasibility of hyperpolarized 129Xe MRI in lung transplant recipients and assess structural and functional pulmonary changes using hyperpolarized 129Xe MRI

NCT ID: NCT05526573 Recruiting - Lung Cancer Clinical Trials

Diagnostic Yeld of Ultrathin Bronchoscopy in Peripheral Pulmonary Lesions

Start date: July 14, 2022
Phase:
Study type: Observational

The use of an ultrathin bronchoscope (UB) has recently been introduced in the diagnosis of peripheral lung lesions. The use of the UB can be supported by navigation systems such as fluoroscopy, ultrasound guidance, electromagnetic navigation, or other technologies, which have complementary potential. Further navigation techniques are still under study. The use of ultrathin instrumentation has already been shown to significantly reduce procedural times compared to traditional instrumentation. The purpose of the study is to prospectively evaluate the institutional experience of different third-level hospital centers with the use of a UB (MP190F; Olympus Medical Systems, Tokyo, Japan) for sampling peripheral lung lesions by means of transbronchial needle aspiration (TBNA) or transbronchial biopsy (TBB), performed after fluoroscopic navigation and simultaneous radial probe-endobronchial ultrasound (RP-EBUS) assessment. Design: multicentric, observational study.